{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T12:27:14Z","timestamp":1791116834310,"version":"4.1.0"},"reference-count":69,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2011,1,31]],"date-time":"2011-01-31T00:00:00Z","timestamp":1296432000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0016172","type":"journal-article","created":{"date-parts":[[2011,1,31]],"date-time":"2011-01-31T21:54:43Z","timestamp":1296510883000},"page":"e16172","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":132,"title":["Efficacy of Fumaric Acid Esters in the R6\/2 and YAC128 Models of Huntington's Disease"],"prefix":"10.1371","volume":"6","author":[{"given":"Gisa","family":"Ellrichmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Petrasch-Parwez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De-Hyung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Reick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa","family":"Arning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Saft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf A.","family":"Linker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2011,1,31]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/00005072-199805000-00001","article-title":"Huntington disease.","volume":"57","author":"JP Vonsattel","year":"1998","journal-title":"J Neuropathol Exp Neurol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1734-1140(10)70238-3","article-title":"Huntington's disease: pathogenesis to animal models.","volume":"62","author":"P Kumar","year":"2010","journal-title":"Pharmacol Rep"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1046\/j.1365-2133.1999.03034.x","article-title":"Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use. The German Fumaric Ester Consensus Conference.","volume":"141","author":"U Mrowietz","year":"1999","journal-title":"Br J Dermatol"},{"key":"ref4","first-page":"103","article-title":"Treatment of psoriasis vulgaris.","volume":"13","author":"W Schweckendiek","year":"1959","journal-title":"Med Monatsschr"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1586\/14737175.8.11.1683","article-title":"Fumarates for the treatment of multiple sclerosis, potential mechanisms of actions and clinical studies.","volume":"8","author":"RA Linker","year":"2008","journal-title":"Expert Rev Neurother"},{"key":"ref6","article-title":"Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway.","author":"RA Linker","journal-title":"Brain"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","article-title":"Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice.","volume":"87","author":"L Mangiarini","year":"1996","journal-title":"Cell"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/cne.20680","article-title":"Chronology of behavioral symptoms and neuropathological sequela in R6\/2 Huntington's disease transgenic mice.","volume":"490","author":"EC Stack","year":"2005","journal-title":"J Comp Neurol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0896-6273(00)80764-3","article-title":"A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmatic toxicity, and selective striatal neurodegeneration.","volume":"23","author":"JG Hodgson","year":"1999","journal-title":"Neuron"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1093\/hmg\/ddg169","article-title":"Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease.","volume":"12","author":"EJ Slow","year":"2003","journal-title":"Hum Mol Genet"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.1523\/JNEUROSCI.0590-05.2005","article-title":"Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington's disease.","volume":"25","author":"JM van Raamsdonk","year":"2005","journal-title":"J Neurosci"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.neuroscience.2006.04.013","article-title":"Differential effects of voluntary physical exercise on behavioral and brain-derived neurotrophic factor expression deficits in Huntington's disease transgenic mice.","volume":"25","author":"TY Pang","year":"2006","journal-title":"Neuroscience"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/35008142","article-title":"Delaying the onset of Huntington's in mice.","volume":"404","author":"A van Dellen","year":"2000","journal-title":"Nature"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0031-9384(98)00343-6","article-title":"Gait Analysis in the Mouse.","volume":"66","author":"KA Clarke","year":"1999","journal-title":"Physiol and Behav"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0092-8674(00)80513-9","article-title":"Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation.","volume":"90","author":"SW Davies","year":"1997","journal-title":"Cell"},{"key":"ref16","first-page":"8473","article-title":"Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntington's disease mice.","volume":"21","author":"H Li","year":"2001","journal-title":"J Neurol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/nm0602-620","article-title":"CNTF is a major protective factor in demyelinating CNS disease: a neurotrophic cytokine as modulator in neuroinflammation.","volume":"8","author":"RA Linker","year":"2002","journal-title":"Nat Med"},{"key":"ref18","article-title":"The mouse brain in stereotaxic coordinates","author":"G Paxinos","year":"2007"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/cne.21272","article-title":"Cellular and subcellular localization of Huntingtin [corrected] aggregates in the brain of a rat transgenic for Huntington disease.","volume":"501","author":"E Petrasch-Parwez","year":"2007","journal-title":"J Comp Neurol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"e1000479","DOI":"10.1371\/journal.pbio.1000479","article-title":"Post-stroke inhibition of induced NADPH oxidase type 4 prevents oxidative stress and neurodegeneration.","volume":"8(9). Pii","author":"C Kleinschnitz","year":"2010","journal-title":"PloS Biol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1523\/JNEUROSCI.19-08-03248.1999","article-title":"Characterization of Progressive Motor Deficits in Mice Transgenic for the Human Huntington's Disease Mutation.","volume":"19","author":"RJ Carter","year":"1999","journal-title":"J Neurosci"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/ana.410410514","article-title":"Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia.","volume":"41","author":"SE Browne","year":"1997","journal-title":"Ann Neurol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1046\/j.1471-4159.2001.00689.x","article-title":"Increased oxidative damage to DNA in a transgenic mouse model of Huntington's disease.","volume":"79","author":"MB Bogdanov","year":"2001","journal-title":"J Neurochem"},{"key":"ref24","first-page":"566","article-title":"Induction of NAD(P)H quinone: oxidoreductase1 inhibits carcinogen-induced aberrant crypt foci in colons of Sprague-Dawley rats.","volume":"12","author":"A Begleiter","year":"2003","journal-title":"Cancer Epidemol Biomarkers Prev"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.bmc.2006.09.053","article-title":"Reactivity of dimethyl fumarate and methylhydrogen fumarate towards glutathione and N-acetyl-L-cysteine-preparation of S-substituted thiosuccinic acid esters.","volume":"15","author":"TJ Schmidt","year":"2007","journal-title":"Bioorg Med Chem"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jneuroim.2005.05.013","article-title":"Detoxication enzyme inducers modify cytokine production in rat mixed glial cells.","volume":"166","author":"A Wierinckx","year":"2005","journal-title":"J Neuroimmunol"},{"issue":"4","key":"ref27","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2174\/187152710791556113","article-title":"Oxidative stress and altered mitochondrial function in neurodegenerative diseases: lessons from mouse models.","volume":"9","author":"JC Fern\u00e1ndez-Checa","year":"2010","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref28","first-page":"25","article-title":"Neurodegenerative diseases: exercising toward neurogenesis and neurodegeneration.","volume":"2","author":"ET Ang","year":"2010","journal-title":"Front Aging Neurosci"},{"issue":"10","key":"ref29","doi-asserted-by":"crossref","first-page":"7266","DOI":"10.3390\/molecules15107266","article-title":"The Nrf2 system as a potantial target for the development of indirect antioxidants.","volume":"15","author":"KA Jung","year":"2010","journal-title":"Molecules"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1046\/j.1471-4159.1998.71010069.x","article-title":"Activation of endogenous antioxidant defenses in neuronal cells prevents free radical-mediated damage.","volume":"71","author":"S Duffy","year":"1998","journal-title":"J Neurochem"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0304-3940(99)00634-5","article-title":"Reduction of H2O2 evoked, intracellular caldium increases in the rat N18-RE-105 neuronal cell line by pretreatment with an electrophilic antioxidant inducer.","volume":"273","author":"JY Su","year":"1999","journal-title":"Neurosci Lett"},{"issue":"7","key":"ref32","doi-asserted-by":"crossref","first-page":"e11769","DOI":"10.1371\/journal.pone.0011769","article-title":"Effects of fumaric acids on cuprizone induced central nervous system de- and remyelination in the mouse.","volume":"5","author":"D Moharregh-Khiabani","year":"2010","journal-title":"PLoS One"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.neulet.2010.03.048","article-title":"Fumaric acid dialkyl esters deprive cultured rat oligodendroglial cells of glutathione and upregulate the expression of heme oxygenase 1.","volume":"475","author":"A Thiessen","year":"2010","journal-title":"Neurosci Lett"},{"issue":"1","key":"ref34","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1073\/pnas.0408487101","article-title":"Protection from mitochondrial complex II inhibition in vitro and in vivo by Nrf2-mediated transcription.","volume":"102","author":"MJ Calkins","year":"2005","journal-title":"Proc Natl Acad Sci"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"37948","DOI":"10.1074\/jbc.M305204200","article-title":"NF-E2-related factor-2 mediates neuroprotection against mitochondrial complex I inhibitors and increased concentrations of intracellular calcium in primary cortical neurons.","volume":"278","author":"JM Lee","year":"2003","journal-title":"J Biol Chem"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1073\/pnas.0505723102","article-title":"Activation of the Keap1\/Nrf2 pathway for neuroprotection by electrophilic [correction of electrophilic] phase II inducers.","volume":"103","author":"T Satoh","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"22925","DOI":"10.1074\/jbc.M414635200","article-title":"Induction of the Nrf2-driven antioxidant response confers neuroprotection during mitochondrial stress in vivo.","volume":"280","author":"AY Shih","year":"2005","journal-title":"J Biol Chem"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.freeradbiomed.2010.03.017","article-title":"Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease.","volume":"49","author":"C Stack","year":"2010","journal-title":"Free Radic Biol Med"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1073\/pnas.0813361106","article-title":"Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: Critical role for the astrocyte.","volume":"24","author":"PC Chen","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1523\/JNEUROSCI.3817-03.2004","article-title":"Nuclear factor E2-related factor 2-dependent antioxidant response element activation by tert-buthylhydroquinone and sulforaphane occuring preferentially in astrocytes conditions neurons against oxidative insult.","volume":"24","author":"AD Kraft","year":"2004","journal-title":"J Neurosci"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1523\/JNEUROSCI.23-08-03394.2003","article-title":"Coordinate regulation of glutathione biosynthesis and release by Nrf2-expressing glia potently protects neurons from oxidative stress.","volume":"23","author":"AY Shih","year":"2003","journal-title":"J Neurosci"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"13574","DOI":"10.1523\/JNEUROSCI.4099-08.2008","article-title":"Nrf2 activation in astrocytes protects against neurodegeneration in mouse models of familial amyotrophic lateral sclerosis.","volume":"28","author":"MR Vargas","year":"2008","journal-title":"J Neurosci"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1002\/eji.1830260916","article-title":"Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate.","volume":"26","author":"R De Jong","year":"1996","journal-title":"Eur J Immunol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"203","DOI":"10.4049\/jimmunol.168.9.4781","article-title":"Dimethylfumarate inhibits TNF-induced nuclear entry of NF-kappa B\/p65 in human endothelial cells.","volume":"168","author":"R Loewe","year":"2002","journal-title":"J Immunol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1046\/j.1365-2133.1998.02400.x","article-title":"The antipsoriatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine network.","volume":"139","author":"HM Ockenfels","year":"1998","journal-title":"Br J Dermatol"},{"key":"ref46","first-page":"29","article-title":"The antipsoriatic dimethyl-fumarate suppresses interferon-gamma-induced ICAM-d1 and HLA-DR expression on hyperproliferative keratinocytes. Quantification by a culture plate-directed APAAP-ELISA technique.","volume":"8","author":"B Sebok","year":"1998","journal-title":"Eur J Dermatol"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1006\/bbrc.1997.6570","article-title":"Dimethylfumarate is an inhibitor of cytokine-induced E-selectin, VCAM-1, and ICAM-1 expression in human endothelial cells.","volume":"234","author":"M Vandermeeren","year":"1997","journal-title":"Biochem Biophys Res Commun"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0306-4522(01)00409-2","article-title":"Essential fatty acids given from conception prevent topographies of motor deficits in a transgenic model of Huntington's disease.","volume":"109","author":"JJ Clifford","year":"2002","journal-title":"Neuroscience"},{"key":"ref49","first-page":"616","article-title":"Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice.","volume":"1762","author":"KM Smith","year":"2006","journal-title":"Biochem Biophys Acta"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"10671","DOI":"10.1073\/pnas.162362299","article-title":"Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease.","volume":"99","author":"CD Keene","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.brainresrev.2008.12.001","article-title":"The R6 lines of transgenic mice: A model for screening new therapies for Huntington's disease.","volume":"59","author":"JM Gil","year":"2009","journal-title":"Brain Res Rev"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"8266","DOI":"10.1523\/JNEUROSCI.22-18-08266.2002","article-title":"Early motor dysfunction and striosomal distribution of huntingtin microaggregates in Huntington's disease knock-in mice.","volume":"22","author":"LB Menalled","year":"2002","journal-title":"J Neurosci"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1046\/j.1471-4159.2000.0750830.x","article-title":"Early alterations in gene expression and cell morphology in a mouse model of Huntington's disease.","volume":"75","author":"C Iannicola","year":"2000","journal-title":"J Neurochem"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"8093","DOI":"10.1073\/pnas.110078997","article-title":"Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease.","volume":"97","author":"M Turmaine","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1523\/JNEUROSCI.23-06-02193.2003","article-title":"Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease.","volume":"23","author":"ZX Yu","year":"2003","journal-title":"J Neurosci"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"9418","DOI":"10.1523\/JNEUROSCI.23-28-09418.2003","article-title":"Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice.","volume":"23","author":"RJ Ferrante","year":"2003","journal-title":"J Neurosci"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1073\/pnas.0437870100","article-title":"Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model af Huntington's disease.","volume":"100","author":"E Hockly","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"6739","DOI":"10.1073\/pnas.110138997","article-title":"Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implication for Huntington's disease therapy.","volume":"97","author":"V Heiser","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1177\/37.8.2666510","article-title":"Quantitative evaluation of Congo red binding to amyloid-like proteins with a beta-pleated sheet conformation.","volume":"37","author":"WE Klunk","year":"1989","journal-title":"J Histochem Cytochem"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nm985","article-title":"Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington's disease.","volume":"10","author":"M Tanaka","year":"2004","journal-title":"Nat Med"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.nbd.2008.01.014","article-title":"Tiagabine is neuroprotective in the N171-82Q and R6\/2 mouse models of Huntington's disease.","volume":"30","author":"N Masuda","year":"2004","journal-title":"Neurobiol Dis"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"8942","DOI":"10.1523\/JNEUROSCI.22-20-08942.2002","article-title":"Therapeutic effects of cystamine in a murine model of Huntington's disease.","volume":"22","author":"A Dedeoglu","year":"2002","journal-title":"J Neurosci"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nm0202-143","article-title":"Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine.","volume":"8","author":"MV Karpuj","year":"2002","journal-title":"Nat Med"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"9158","DOI":"10.1074\/jbc.273.15.9158","article-title":"Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containig the polyglutamine tract.","volume":"273","author":"CL Wellington","year":"1998","journal-title":"J Biol Chem"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/80538","article-title":"Minocycline inhibitis caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington's disease.","volume":"6","author":"M Chen","year":"2000","journal-title":"Nat Med"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/ana.10614","article-title":"Minocycline and doxycycline are not beneficial in a model of Huntington's disease.","volume":"54","author":"DL Smith","year":"2003","journal-title":"Ann Neurol"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"10483","DOI":"10.1073\/pnas.1832501100","article-title":"Minocycline inhibits caspase-independent and \u2013dependent mitochondrial cell death pathways in models of Huntington's disease.","volume":"100","author":"X Wang","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"e9793","DOI":"10.1371\/journal.pone.0009793","article-title":"Comprehensive behavioral testing in the R6\/2 mouse model of Huntington's disease shows no benefit from CoQ10 or Minocycline.","volume":"5","author":"LB Menalled","year":"2010","journal-title":"Plos One"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.nbd.2009.05.007","article-title":"Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models.","volume":"35","author":"LB Menalled","year":"2009","journal-title":"Neurobiol Dis"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0016172","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,8]],"date-time":"2019-06-08T07:11:41Z","timestamp":1559977901000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0016172"}},"subtitle":[],"editor":[{"given":"Christoph","family":"Kleinschnitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2011,1,31]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2011,1,31]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0016172","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,31]]}}}